ZYME Quote, Financials, Valuation and Earnings

IDEAYA Biosciences, Inc. has a net margin of -70.99% compared to Zymeworks, Inc.'s net margin of 57.38%. Zymeworks, Inc.'s return on equity of -18.82% beat IDEAYA Biosciences, Inc.'s return on equity of -15.12%.

Zymeworks, Inc. has a consensus price target of $34.50, signalling upside risk potential of 31.58%. On the other hand IDEAYA Biosciences, Inc. has an analysts' consensus of $49.47 which suggests that it could grow by 37.38%. Given that IDEAYA Biosciences, Inc. has higher upside potential than Zymeworks, Inc., analysts believe IDEAYA Biosciences, Inc. is more attractive than Zymeworks, Inc..

Zymeworks, Inc. has a beta of 1.269, which suggesting that the stock is 26.869% more volatile than S&P 500. In comparison IDEAYA Biosciences, Inc. has a beta of 0.040, suggesting its less volatile than the S&P 500 by 96.023%.

Zymeworks, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IDEAYA Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks, Inc. pays -- of its earnings as a dividend. IDEAYA Biosciences, Inc. pays out -- of its earnings as a dividend.

Zymeworks, Inc. quarterly revenues are $27.6M, which are smaller than IDEAYA Biosciences, Inc. quarterly revenues of $207.8M. Zymeworks, Inc.'s net income of -$19.6M is lower than IDEAYA Biosciences, Inc.'s net income of $119.2M. Notably, Zymeworks, Inc.'s price-to-earnings ratio is -- while IDEAYA Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks, Inc. is 14.77x versus 14.83x for IDEAYA Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of -70.99% compared to Zymeworks, Inc.'s net margin of -82.06%. Zymeworks, Inc.'s return on equity of -18.82% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Zymeworks, Inc. has a consensus price target of $34.50, signalling upside risk potential of 31.58%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $85.47 which suggests that it could grow by 4.43%. Given that Zymeworks, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Zymeworks, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Zymeworks, Inc. has a beta of 1.269, which suggesting that the stock is 26.869% more volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.

Zymeworks, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Zymeworks, Inc. quarterly revenues are $27.6M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Zymeworks, Inc.'s net income of -$19.6M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Zymeworks, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks, Inc. is 14.77x versus 13.93x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Jazz Pharmaceuticals Plc has a net margin of -70.99% compared to Zymeworks, Inc.'s net margin of 22.33%. Zymeworks, Inc.'s return on equity of -18.82% beat Jazz Pharmaceuticals Plc's return on equity of -9.16%.

Zymeworks, Inc. has a consensus price target of $34.50, signalling upside risk potential of 31.58%. On the other hand Jazz Pharmaceuticals Plc has an analysts' consensus of $208.50 which suggests that it could grow by 24.78%. Given that Zymeworks, Inc. has higher upside potential than Jazz Pharmaceuticals Plc, analysts believe Zymeworks, Inc. is more attractive than Jazz Pharmaceuticals Plc.

Zymeworks, Inc. has a beta of 1.269, which suggesting that the stock is 26.869% more volatile than S&P 500. In comparison Jazz Pharmaceuticals Plc has a beta of 0.305, suggesting its less volatile than the S&P 500 by 69.522%.

Zymeworks, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks, Inc. pays -- of its earnings as a dividend. Jazz Pharmaceuticals Plc pays out -- of its earnings as a dividend.

Zymeworks, Inc. quarterly revenues are $27.6M, which are smaller than Jazz Pharmaceuticals Plc quarterly revenues of $1.1B. Zymeworks, Inc.'s net income of -$19.6M is lower than Jazz Pharmaceuticals Plc's net income of $251.4M. Notably, Zymeworks, Inc.'s price-to-earnings ratio is -- while Jazz Pharmaceuticals Plc's PE ratio is 15.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks, Inc. is 14.77x versus 2.45x for Jazz Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -70.99% compared to Zymeworks, Inc.'s net margin of 21.47%. Zymeworks, Inc.'s return on equity of -18.82% beat Johnson & Johnson's return on equity of 33.27%.

Zymeworks, Inc. has a consensus price target of $34.50, signalling upside risk potential of 31.58%. On the other hand Johnson & Johnson has an analysts' consensus of $202.54 which suggests that it could fall by -1.36%. Given that Zymeworks, Inc. has higher upside potential than Johnson & Johnson, analysts believe Zymeworks, Inc. is more attractive than Johnson & Johnson.

Zymeworks, Inc. has a beta of 1.269, which suggesting that the stock is 26.869% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Zymeworks, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.5% to investors and pays a quarterly dividend of $1.30 per share. Zymeworks, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zymeworks, Inc. quarterly revenues are $27.6M, which are smaller than Johnson & Johnson quarterly revenues of $24B. Zymeworks, Inc.'s net income of -$19.6M is lower than Johnson & Johnson's net income of $5.2B. Notably, Zymeworks, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 19.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks, Inc. is 14.77x versus 5.40x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.